Zenshine Pharma to Present the Latest Results at AACR Annual Meeting 2022
First patient receives ZX-101A treatment in China
First patient received ZX-4081 treatment in the phase 1 trial
NMPA Approved Zenshine’s IND Application for ZX-101A as solid tumor treatment
NMPA Approved Zenshine’s IND Application for ZX-7101A as influenza treatment
First patient with advanced solid tumor receives ZX-101A treatment in China
Zenshine Announced Dr. Xiaoli Qin as Chief Science Officer
Zenshine Receives US FDA IND Approval to Initiate Clinical Trial for ZX-4081
Zenshine Pharma Announces Completion of Series A+ Financing
Zenshine Pharma releases four new research results at the AACR 2021
The first patient received ZX-101A treatment in the United States
Zenshine Pharma will present important research results at the AACR 2021
Zenshine Pharma Raised $15 Million in Series A Financing
Zenshine’s first IND approval by the US FDA
